The Immunology and Biologics Educational Collaborative (IBEC) represents a coalition of organizations dedicated to advancing education and best practices related to the use of biologics in the care for patients with immune-mediated inflammatory disorders. IBEC is directed under the leadership of Leonard Calabrese, DO, Professor of Medicine, Cleveland Clinic with a focus on building and reinforcing foundational knowledge and application of key concepts in immunology as they relate to clinical care. Earn CME on Immunology and Biologics, Osteoarthritis, and Rheumatoid Arthritis through videos, slides/audio lectures and tutorials. Visit the IBEC website to learn more.
The recent advent of biologic disease modifying anti-rheumatic drugs (DMARDs) has transformed the rheumatoid arthritis (RA) treatment landscape from symptom management to disease modification. Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of inflammatory processes leading to progressive joint destruction, systemic inflammation, and extra-articular manifestations. With recent approvals of new, first-in-class, biologic DMARDs with novel mechanisms of action, disability is no longer an inevitable outcome for patients with RA. These agents modify disease progression by targeting key mediators of inflammation. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as efficacy profiles of current and emerging DMARDs. In this forum, leading rheumatologists will integrate discussions of basic immunologic principles with current and emerging RA treatments. Mechanisms of autoimmunity and inflammation will be juxtaposed against the emerging role of B-cell and T-cell targeting therapies in addition to the use of small molecules in novel treatment approaches.